SMPD4 mediated sphingolipid metabolism regulates brain and primary cilia development.
Ceramide
Cerebellar hypoplasia
IPSCs
Microcephaly
Mouse
Primary cilia
SMPD4
Sphingolipids
Journal
Development (Cambridge, England)
ISSN: 1477-9129
Titre abrégé: Development
Pays: England
ID NLM: 8701744
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
20
12
2023
accepted:
18
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
Genetic variants in multiple sphingolipid biosynthesis genes cause human brain disorders. A recent study collected patients from twelve unrelated families with variants in the gene SMPD4, a neutral sphingomyelinase which metabolizes sphingomyelin into ceramide at an early stage of the biosynthesis pathway. These patients have severe developmental brain malformations including microcephaly and cerebellar hypoplasia. The disease mechanism of SMPD4 was not known and we pursued a new mouse model. We hypothesized that the role of SMPD4 in producing ceramide is important for making primary cilia, a crucial organelle mediating cellular signaling. We found that the mouse model has cerebellar hypoplasia due to failure of Purkinje cell development. Human induced pluripotent stem cells exhibit neural progenitor cell death and have shortened primary cilia which is rescued by adding exogenous ceramide. SMPD4 production of ceramide is crucial for human brain development.
Identifiants
pubmed: 39470011
pii: 362494
doi: 10.1242/dev.202645
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
ID : R35GM131875
Pays : United States
Organisme : National Institute of Child Health and Human Development
ID : F31HD104350
Informations de copyright
© 2024. Published by The Company of Biologists Ltd.